Medifast (MED)
NYSE:MED
Want to see MED full AI Analyst Report?
MED Stock Chart & Stats
$10.97
-$0.62(-3.78%)
At close: 4:00 PM EST
$10.97
-$0.62(-3.78%)
Day’s Range― - ―
52-Week Range$9.22 - $15.46
Previous CloseN/A
Volume160.90K
Average Volume (3M)273.17K
Market Cap
$139.99M
Enterprise Value$84.56M
Total Cash (Recent Filing)$167.27M
Total Debt (Recent Filing)$16.79M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Aug 10, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding11,119,115
10 Day Avg. Volume240,932
30 Day Avg. Volume273,171
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.59
Price to Sales (P/S)0.30
P/FCF Ratio93.90
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue0.22
Enterprise Value/Gross Profit0.31
Enterprise Value/Ebitda58.16
Forecast
1Y Price Target
$12.00Price Target Upside9.39% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-2.03
Revenue Forecast (FY)$273.70M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet & LiquidityA strong cash position with no debt and meaningful working capital provides durable runway for the planned turnaround and product rollout. This reduces short-term refinancing risk and gives management flexibility to fund marketing, pilot programs, and restructuring without immediate external financing.
Coach Productivity ImprovementRising revenue per coach is a leading operational indicator showing stronger monetization of the existing field. Higher coach productivity can sustain revenue recovery even before coach count expands, improving unit economics, margin recovery potential, and the efficiency of customer acquisition over the medium term.
Clinical Differentiation & Product PipelineA differentiated metabolic-health product backed by clinical outcomes supports a structural repositioning away from commoditized weight-loss. Proprietary ingredient technology and clinical evidence can increase customer stickiness, justify premium pricing, and help rebuild coach relevance against secular headwinds like GLP-1 adoption.
Bears Say
Multi-year Revenue Decline & Profitability DeteriorationSustained revenue declines and the swing to losses indicate structural demand and margin pressure. Lost operating leverage and negative net margins reduce internal funding for growth and increase dependence on executing a successful turnaround, making durable profitability recovery uncertain over the next several quarters.
Severe Drop In Active Earning CoachesThe business is reliant on its coach network for acquisition and retention; a near-45% decline sharply reduces distribution reach, recurring purchase drivers, and referral volume. Rebuilding coach count is time-consuming and may be structurally constrained by competing weight-loss modalities like GLP-1s.
Weakened Cash Generation & Thin Free Cash FlowOperating and free cash flow have compressed to very low levels, limiting the company's ability to self-fund marketing, product launches, or incremental field incentives if losses persist. Even with a strong cash balance, weak cash conversion raises execution and liquidity risk if recovery delays occur.
Medifast News
MED FAQ
What was Medifast’s price range in the past 12 months?
Medifast lowest stock price was $9.22 and its highest was $15.46 in the past 12 months.
What is Medifast’s market cap?
Medifast’s market cap is $139.99M.
When is Medifast’s upcoming earnings report date?
Medifast’s upcoming earnings report date is Aug 10, 2026 which is in 93 days.
How were Medifast’s earnings last quarter?
Medifast released its earnings results on May 04, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.52 by $0.33.
Is Medifast overvalued?
According to Wall Street analysts Medifast’s price is currently Undervalued.
Does Medifast pay dividends?
Medifast pays a Quarterly dividend of $1.65 which represents an annual dividend yield of N/A. See more information on Medifast dividends here
What is Medifast’s EPS estimate?
Medifast’s EPS estimate is -0.65.
How many shares outstanding does Medifast have?
Medifast has 11,119,115 shares outstanding.
What happened to Medifast’s price movement after its last earnings report?
Medifast reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.52. Following the earnings report the stock price went up 22.484%.
Which hedge fund is a major shareholder of Medifast?
Currently, no hedge funds are holding shares in MED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medifast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.00 (9.39% Upside)
$12.00 (9.39% Upside)
Blogger Sentiment
Bullish
MED Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 294.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $178.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.05%
12-Months-Change
Fundamentals
Return on Equity
-8.89%
Trailing 12-Months
Asset Growth
-12.35%
Trailing 12-Months
Company Description
Medifast
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
MED Company Deck
MED Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear early operational and scientific progress — notably improving coach productivity, sequential revenue stabilization, a strong cash position, cost-savings initiatives, and a defined metabolic-health product roadmap — against substantial near-term financial headwinds, including a 34% YoY revenue decline, a roughly 45% drop in active earning coaches, compressed gross margins, and continued net losses. Management is optimistic about trajectory and expects profitability improvements beginning in Q4 2026 contingent on execution and the new product rollout, but material risks remain.View all MED earnings summariesMED Stock 12 Month Forecast
Average Price Target
$12.00
▲(9.39% Upside)
Technical Analysis
Ownership Overview
5.28% Insiders
14.32% Mutual Funds
3.68% Other Institutional Investors
56.33% Public Companies and
Individual Investors